Isabelle L. B.
- Country
- France
- Department
- Département des maladies du système nerveux
Research Overview
- Efficacy and Safety Evaluation of Latozinemab in Patients with Frontotemporal Dementia Due to Progranulin Gene Mutations: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
- Continuation Study of Latozinemab in Patients with Neurodegenerative Diseases Following Prior Participation in Alector-Sponsored Trials
- A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of LY3884963 in Patients with Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN) (PROCLAIM)
Data & Insights
Has run more than one trial at 15 of 35 partner sites.
Specializations
Alzheimer's disease and neurodegenerative disorders
Clinical research activity is centered on Alzheimer's disease, including early symptomatic and preclinical stages, as well as related cognitive and behavioral manifestations. The portfolio also extends to broader neurodegenerative diseases and movement disorders relevant to memory-clinic practice.
- Early Alzheimer's disease
- Alzheimer's disease psychosis
- Parkinson's disease
- Dementia with Lewy bodies
Work in this area reflects a strong therapeutic interest in cognitive decline, neuropsychiatric symptoms, and disease-modifying strategies for disorders of memory and brain aging.
Autoimmune disease and systemic inflammatory disorders
The investigator is involved in trials across systemic autoimmune rheumatic diseases, with emphasis on conditions affecting the joints, kidneys, lungs, and skin. This includes disorders with chronic inflammatory activity and immune-mediated organ damage.
- Systemic lupus erythematosus
- Lupus nephritis
- Sjögren's syndrome
- Rheumatoid arthritis
Additional therapeutic interest includes vasculitis, myositis, systemic sclerosis, and inflammatory skin disease, with attention to immune control and preservation of organ function.
Hematologic malignancies and cellular therapies
Research involvement spans a wide range of blood cancers, including acute and chronic leukemias, lymphomas, and plasma cell disorders. The investigator is also active in studies of targeted therapies and cell-based immunotherapies for relapsed or refractory disease.
- Acute lymphoblastic leukemia
- Acute myeloid leukemia
- Chronic lymphocytic leukemia
- Diffuse large B-cell lymphoma
Therapeutic interests also include multiple myeloma, follicular lymphoma, and myelodysplastic syndromes, with a focus on innovative treatment options in difficult-to-treat hematologic disease.
Gastroenterology, hepatology, and inflammatory bowel disease
The clinical profile includes trials in liver disease, portal hypertension, and metabolic liver disorders, alongside chronic inflammatory diseases of the intestine. These areas indicate sustained interest in digestive and hepatobiliary therapeutics.
- Hepatocellular carcinoma
- Primary sclerosing cholangitis
- Crohn's disease
- Ulcerative colitis
Additional activity includes non-alcoholic steatohepatitis, cirrhosis, and gastroesophageal cancer, with emphasis on therapeutic innovation in chronic and advanced digestive disease.
Cardiovascular, respiratory, and renal disease
Trial involvement also covers cardiovascular disease, heart failure, arrhythmia, and thromboembolic disease, together with major respiratory and kidney disorders. This reflects a broad therapeutic interest in high-burden internal medicine conditions.
- Acute myocardial infarction
- Pulmonary arterial hypertension
- Chronic kidney disease
- Idiopathic pulmonary fibrosis
Further focus includes acute kidney injury, stroke, asthma, and chronic obstructive pulmonary disease, supporting research across complex cardiopulmonary and renal therapeutics.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.